Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.9% Higher – Here’s What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price traded up 6.9% on Friday . The stock traded as high as $3.65 and last traded at $3.6790. 8,986,944 shares were traded during trading, a decline of 50% from the average daily volume of 17,956,109 shares. The stock had previously closed at $3.44.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen upgraded Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Finally, Morgan Stanley set a $5.30 price objective on Recursion Pharmaceuticals in a research report on Monday, August 17th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $8.06.

Recursion Pharmaceuticals Price Performance

The company has a market capitalization of $1.94 billion, a PE ratio of -3.48 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.03 and a quick ratio of 5.03. The stock’s 50 day simple moving average is $3.33 and its 200-day simple moving average is $3.33.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. The business had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. During the same period in the previous year, the business posted ($0.41) EPS. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $3.34, for a total value of $100,200.00. Following the completion of the transaction, the director owned 6,158,287 shares in the company, valued at $20,568,678.58. The trade was a 0.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 103,963 shares of company stock valued at $368,702 over the last 90 days. 6.65% of the stock is owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. International Assets Investment Management LLC purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $31,000. Integral Investment Advisors Inc. purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $39,000. Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $41,000. MQS Management LLC acquired a new stake in Recursion Pharmaceuticals during the first quarter worth approximately $41,000. Finally, Fund Advisors of America Inc FL acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter worth about $45,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.